| Full text | |
| Author(s): |
Soares, Ciro Dantas
[1, 2]
;
de Caceres, Cinthia Veronica Bardalez Lopez
[1]
;
Rodrigues-Fernandes, Carla Isabelly
[1]
;
de Lima Morais, Thayna Melo
[1]
;
de Almeida, Oslei Paes
[1]
;
de Carvalho, Maria Goretti Freire
[2]
;
Fonseca, Felipe Paiva
[3]
Total Authors: 7
|
| Affiliation: | [1] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Oral Diag, Area Pathol, Piracicaba, SP - Brazil
[2] Private Pathol Serv, Natal, RN - Brazil
[3] Univ Fed Minas Gerais, Sch Dent, Dept Oral Surg & Pathol, Belo Horizonte, MG - Brazil
Total Affiliations: 3
|
| Document type: | Journal article |
| Source: | ORAL DISEASES; v. 27, n. 2 JUL 2020. |
| Web of Science Citations: | 0 |
| Abstract | |
Objective In the present study, we aimed to investigate the prognostic value of RUNX1 expression in 76 patients with adenoid cystic carcinoma (ACC). Materials and Methods All cases were arranged in tissue microarray blocks and submitted to immunohistochemistry against RUNX1. These results were statistically correlated with clinicopathologic features, including age, gender, tumour site, tumour size, lymph node status, AJCC clinical stage, distant metastasis, treatment, recurrences, follow-up, histologic pattern, vascular and neural invasion, all of which obtained from patient's medical records. Results RUNX1 was expressed in the nuclei of tumour cells, with a mean of 18.1% of positivity. Nuclear RUNX1 expression was significantly associated with AJCC clinical stage (p < .0001), solid histologic pattern (p < .0001), vascular invasion (p < .0001) and presence of local recurrence (p < .0001). Using univariate and multivariate analyses, RUNX1 nuclear expression was significantly associated with a lower disease-free survival (p p = .028, respectively) and disease-specific survival (p p = .018, respectively) rates. Conclusion In summary, RUNX1 nuclear expression may represent an indicator of unfavourable outcome for patients affected by head and neck ACC. (AU) | |
| FAPESP's process: | 15/25905-1 - Akt, COX-2, RUNX1 and MMPs expression in metastatic melanomas and Biotechnology prospection of molecules with antineoplastic activity |
| Grantee: | Ciro Dantas Soares |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 17/16102-8 - Akt, COX-2, RUNX1 and MMPs expression in metastatic melanomas |
| Grantee: | Jacks Jorge Junior |
| Support Opportunities: | Regular Research Grants |